The State of the World Economy in One Chart

13 years ago

By WallStreetDaily.com The complexity of global economies and the financial market can make it difficult to simply understand what’s going…

Can These “Tricks” Keep the Stock Market High Much Longer?

13 years ago

By Profit ConfidentialRemember the famous words of Mark Twain: “Whenever you find yourself on the side of the majority, it’s…

Why I Like This Blue Chip So Much (55th Dividend Increase Just Announced)

13 years ago

By Profit ConfidentialIn the world of large-cap blue chips, the performance of so many mature, slow-growth corporations in the market…

Your Portfolio Stopped Growing? Here’s Why You Really Need to Think Chinese

13 years ago

By Profit Confidential China is not dead for investments, folks! In my previous article, I talked about the travel sector…

Scary Story on the Booming Auto Sales No One Is Talking About

13 years ago

By Profit ConfidentialAutomakers in the U.S. economy are getting a significant amount of attention these days because they are selling…

Chinese Economy Screaming “Troubles Ahead” for Global Economy?

13 years ago

By Profit ConfidentialI keep a keen eye on the second-biggest economy in the world simply because China is experiencing an…

This Hot IPO Still Worth Following After Major Market Upswing

13 years ago

By Profit ConfidentialWhile valuations are almost always stretched in the world of new listings, there have been some very attractive…

My Favorite Stock in the Rising Chinese Travel Market

13 years ago

By Profit ConfidentialThe airline sector has reorganized over the past few years, with mergers and route cuts that have resulted…

USDJPY stays in a upward price channel

13 years ago

USDJPY stays in a upward price channel on 4-hour chart, and remains in uptrend from 95.81, the price action from…

Griffin Securities’ Keith Markey Gives Performance Reviews on Four Favorite Biotech Names

13 years ago

Source: Peter Byrne of The Life Sciences Report (9/12/13) http://www.thelifesciencesreport.com/pub/na/griffin-securities-keith-markey-gives-performance-review-on-four-top-biotech-names As science director for Griffin Securities, Keith Markey knows his…